CHRN trades 36.1% above Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHRN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 17, 2026, ChronoScale Corporation (CHRN) has a Wall Street consensus price target of $6.00, based on estimates from 4 covering analysts. With the stock currently trading at $9.39, this represents a potential downside of -36.1%. The company has a market capitalization of $33M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CHRN trades at a trailing P/E of -2.1x. Analysts expect EPS to grow +97.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MYOMyomo, Inc. | $39M | $1.02 | — | — | — | — | — |
NVCRNovocure Ltd | $1.3B | $11.30 | $26.00 | +130.1% | Buy | — | 15 |
GMEDGlobus Medical, Inc. | $9.5B | $70.50 | $93.13 | +32.1% | Buy | 14.1x | 37 |
ISRGIntuitive Surgical, Inc. | $154.6B | $437.75 | $485.44 | +10.9% | Buy | 38.9x | 57 |
ABTAbbott Laboratories | $187.2B | $107.45 | $121.36 | +12.9% | Buy | 19.5x | 43 |
MDTMedtronic plc | $132.1B | $102.88 | $97.73 | -5.0% | Buy | 17.2x | 51 |
SYKStryker Corporation | $119.1B | $310.72 | $354.47 | +14.1% | Buy | 20.9x | 52 |
ZBHZimmer Biomet Holdings, Inc. | $19.6B | $101.41 | $109.11 | +7.6% | Hold | 11.9x | 42 |
RGENRepligen Corporation | $9.2B | $162.78 | $198.00 | +21.6% | Buy | 78.5x | 24 |
NVDANVIDIA Corporation | $3.8T | $156.14 | $339.17 | +117.2% | Buy | 16.8x | 79 |
Quick answers to the most common questions about buying CHRN stock.
CHRN's consensus price target is $6, -36.1% below the current price of $9.39. The 4 analysts tracking CHRN see downside risk at present valuations.
CHRN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies -36.1% downside from current levels.
CHRN's current price is $9.39 with a consensus target of $6 (-36.1% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for CHRN, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
CHRN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHRN stock forecast based on 4 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Analysts are cautious on CHRN, with 0 Sell ratings and a price target of $6 (-36.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHRN analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.